Skip to content
XPR – Lifestyle Demo
Author:
FibroBiologics, Inc.
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
April 30, 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements
April 20, 2026
FibroBiologics Announces Closing of $3 Million Public Offering
April 2, 2026
FibroBiologics Announces Pricing of $3 Million Public Offering
March 31, 2026
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
March 31, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
March 25, 2026
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
March 12, 2026
←
Previous Page
1
2